The need to develop more effective therapies for lung cancer has led to investigations in understanding the molecular mechanisms of the differentiation process, in particular neuroendocrine (NE) differentiation. Recent studies have demonstrated that NE differentiation in nonsmall cell lung carcinoma (NSCLC) is not uncommon. Those NSCLCs with NE differentiation are considered a form of in transition NE carcinoma and show a more aggressive clinical course compared with NSCLC without NE differentiation. 25.1, a novel protein interacting with mac25/insulin-like growth factor-binding protein-related protein 1 (mac25/IGFBP-rP1), induced NE-like differentiation when collectively overexpressed in M12 prostate cancer cells. We have examined mac25/IGFBP-rP1 and 25.1 as potential molecular regulators in vitro of the NEdifferentiation process in lung cancer. In a panel of SCLC and NSCLC cell lines, mac25/IGFBP-rP1 and 25.1 were expressed at higher levels in SCLC. An increase and sustained activation of adenosine 3 0 ,5 0 -cyclic monophosphate (cAMP) levels induced NE-like differentiation in NSCLC cell lines, and a concomitant increase in the expression of mac25/IGFBP-rP1 and 25.1 was observed during the cAMP-regulated differentiation of NCI-H157 cells, suggesting the involvement of these proteins. Furthermore, the collective overexpression of mac25/ IGFBP-rP1 and 25.1 in NSCLC cells induced NE-like differentiation as early as 6 h postinfection. The present data suggest that mac25/IGFBP-rP1 and 25.1 may play a functional role in the NE differentiation of NSCLC cell lines and may provide a novel therapeutic target for treating lung cancers, in particular NSCLC with NE differentiation.
Introduction
Lung cancer is a predominant cause of cancer death in both men and women (for a review, see Cersosimo, 2002) . Although current therapies for patients diagnosed with lung cancer may include surgical resection and/or radiotherapy or chemotherapy, the outcome is poor with an overall 5-year survival rate of 15% (1992 American Cancer Society Surveillance Research, 2002) . With the need to develop more effective therapies for treating lung cancer, much attention is now focused on neuroendocrine (NE) differentiation as both a predictor of therapeutic outcome and as a target for established and novel therapies (Wallace, 2002) .
Lung cancer is heterogeneous and histologically divided into two main groups. Small cell lung carcinomas (SCLCs), which constitute 15-20% of cases in the USA, show rapid growth and early metastases (reviewed by Cersosimo, 2002) . Non-SCLCs (NSCLCs) constitute a larger heterogeneous population of tumors subdivided into squamous, adenocarcinoma and large cell carcinomas (Cersosimo, 2002) . Despite their aggressiveness, SCLC have a better initial response to chemotherapy than NSCLC, perhaps due to their neuroendocrine factors (Skov et al., 1991; Carnaghi et al., 2001) . NEneoplasms are characterized by cytoplasmic dense-core neurosecretory granules synthesizing neuropeptides and receptors (Cersosimo, 2002) . These autocrine/paracrine mechanisms involving the release of neuropeptides may contribute to this responsiveness but also have been proposed to contribute to disease progression (Reynolds et al., 2000) . Foci of NE cells have been identified in 10-35% of all NSCLC tumors (NSCLC-NE) (Gazdar et al., 1988; Graziano et al., 1994; Linnoila et al., 1994; Wallace, 2002) . Previously, these NSCLC-NE tumors had been postulated to be an intermediary step between NSCLC and SCLC (Graziano et al., 1994; Linnoila et al., 1994) , and to show, like SCLC, a favorable early response to chemotherapy and a correlation to early dissemination and metastases (Berendsen et al., 1989; Shaw et al., 1993; Graziano et al., 1994; Linnoila et al., 1994; Schleusener et al., 1996; Iyoda et al., 2001) . More recent studies question this idea, and suggest that more knowledge must be obtained before a full understanding of any correlation of NE-like characteristics of lung cancer cells and response to therapy can be determined (Jiang et al., 1999; Graziano et al., 2001; Yesner, 2001; Gajra et al., 2002) .
The molecular regulation of the NE differentiation process in lung cancer is still unclear. In models of prostate cancer, it has been proposed that NE differentiation is the outcome of a complex interplay involving extracellular signals and crosstalk between key signaling pathways leading to transcriptional regulation. In vitro and in vivo prostate cancer models have shown that discrete changes in cellular microenvironments, such as androgen withdrawal or epidermal growth factor (EGF), IL-6, epinephrine, forskolin and adenosine 3 0 , 5 0 -cyclic monophosphate (cAMP) administration, can each induce NE differentiation (Vossler et al., 1997; Chen et al., 1999; Cox et al., 2000; Deeble et al., 2001) . In prostate cancer cells, induction of cAMP-dependent protein kinase (PKA) can lead to the activation of the mitogen-activated protein kinase (MAPK) pathway (Vossler et al., 1997; Chen et al., 1999) and cause NE differentiation (Vossler et al., 1997) . Interestingly, cotreatment by PKA activators with IL-6 enhances MAPK activation and NE differentiation of LNCaP prostate cancer cells, perhaps reflecting a contribution from the tumor environment (Deeble et al., 2001) .
Recently a novel protein, 25.1, identified as a key interacting protein to mac25/insulin-like growth factorbinding protein-related protein 1 (mac25/IGFBP-rP1), was shown through its interaction with mac25/IGFBPrP1 to enhance the cellular differentiation of M12 prostate cancer cells . This enhanced cellular differentiation exhibited characteristics of NElike differentiation, suggesting a potential complementary or alternate means for the molecular regulation of the NE-differentiation process in prostate cancer cells. Originally termed mac25, the human mac25/IGFBP-rP1 was first identified and cloned as a downregulated gene in meningiomas (Murphy et al., 1993) . It was later identified as a key gene upregulated in senescent human mammary epithelial cells where, based on its high homology to the N-terminal amino acids of the IGFBP family of proteins, it was proposed to be a member of the IGFBP family (Swisshelm et al., 1995; Hwa et al., 1999) . It has since been shown that mac25/IGFBP-rP1 is able to bind both IGFs and insulin with low affinity, and has been implicated in cellular senescence, tumor suppression and proliferation (Swisshelm et al., 1995; Akaogi et al., 1996; Sprenger et al., 1999) .
The NE-differentiation process in lung cancer cells is unclear. The MAPK pathway via Raf-1 and activated protein kinase C (PKC) has been implicated in the regulation of growth and differentiation of SCLC cells by neuropeptides (Heasley, 2001; Jull et al., 2001) , while the regulation of NE differentiation of NSCLC has yet to be described. In the present study, we investigated the interaction of mac25/IGFBP-rP1 and 25.1 and their potential role in NE differentiation of NSCLC lung cancer cells. The data presented suggest that the interaction of mac25/IGFBP-rP1 and 25.1 induces NE differentiation of NSCLC cell lines and could provide a novel therapeutic target.
Results
SCLCs express high levels of mac25/IGFBP-rP1 and 25.1 protein On the basis that SCLC typically exhibit a more pronounced NE phenotype when compared with NSCLC, we first characterized the endogenous expression pattern of mac25/IGFBP-rP1 and 25.1 in a representative panel of NSCLC and SCLC cell lines to establish a link between the NE phenotype of cells and the expression of mac25/IGFBP-rP1 and 25.1. When cultured either in serum-containing medium (SCM) or serum-free medium (SFM), mac25/IGFBP-rP1 and 25.1 proteins were endogenously expressed in both NSCLC and SCLC (Figure 1) . A greater expression of the NE marker neuron specific enolase (NSE) in SCLC was paralleled by an increased expression of both mac25/ IGFBP-rP1 and 25.1 (Figure 1 ). These results indicate that the expression of mac25/IGFBP-rP1 and 25.1 may be positively correlated to NE characteristics. Overall, this suggests that mac25/IGFBP-rP1 and 25.1 are either an outcome of the differentiation process or they play a functional role in the NE phenotype of lung cancer cells.
Exogenous administration of cAMP/IBMX induces NElike differentiation in the poorly differentiated squamous NSCLC cell line To investigate whether the induction of NE-like differentiation of NSCLC cells may influence mac25/ IGFBP-rP1 and 25.1 levels, the squamous NCI-H157 and adenocarcinoma Lu-CSF-1 cell lines, expressing different endogenous levels of mac25/IGFBP-rP1 and 25.1 (Figure 1 ), were treated with an analog of cAMP (8-bromo-cAMP) in the presence or absence of the phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine (IBMX) to sustain cAMP activity. Previous studies have documented that combined 8-bromocAMP and IBMX treatments induced NE differentiation in prostate cancer cell lines via the PKA signaling pathway (Cox et al., 2000) . Following an evaluation of Figure 1 Endogenous expression of mac25/IGFBP-rP1 and 25.1 is elevated in SCLC when compared to NSCLC cell lines. WCL (20 mg) from a panel of NSCLC and SCLC cell lines were investigated for the endogenous expression of mac25/IGFBP-rP1, 25.1 and NSE by WIB. Results were normalized to a-tubulin. Control: controls for mac25/IGFBP-rP1 and 25.1; secreted mac25/ IGFBP-rP1 protein from Hs578T and baculovirus produced 25.1, respectively. The figure is representative of three independent experiments. cell toxicity with increasing concentrations of cAMP and IBMX, a morphological evaluation of NCI-H157 and Lu-CSF-1 cell lines after 72 h revealed that with 0.5 mM cAMP/0.5 mM IBMX the cells underwent a phenotypic change, characterized by the presence of an extended slender morphology and dendritic-like processes in a variety of stages (Figure 2a ). These changes were more striking in the NCI-H157 cells, while for Lu-CSF-1 cells morphological changes were subtle. Both cell lines also exhibited a decrease in cell density (Figure 2a ) following cAMP or cAMP/IBMX treatments in SFM or SCM, which was verified quantitatively by trypan blue cell counts and MTT assays (data not shown).
To determine whether the observed cAMP/IBMXinduced change was NE-like, the expression of known NE markers in lung cancer (chromogranin A (ChrA) and NSE) was investigated by two independent methodologies following treatments with cAMP/IBMX combinations for 72 h in both SCM and SFM. The cellular expression of the NE marker ChrA, shown by immunocytochemistry, was induced in both cell lines when treated with either cAMP or cAMP/IBMX combinations ( Figure 2b ). Higher expression of ChrA and its induction by IBMX treatment alone in Lu-CSF-1 cells was also observed (Figure 2b) . Likewise, the expression of NSE in NCI-H157 cell lysates increased with cAMP, IBMX and more significantly with cAMP/ IBMX combinations, while little change was observed for Lu-CSF-1 cells (Figure 2c) . Overall, the cAMP/ IBMX combination led to the most significant NE-like differentiation in both NSCLC lung cancer cell lines, influencing both cellular morphology, cell density and the expression of NE markers. While these effects were more dramatic in the NCI-H157 Squamous cell line, it appears 'based on these results' that distinct NE-like phenotypes are induced in these cell lines by increasing cAMP.
The cAMP/IBMX induced NE-like differentiation in the poorly differentiated NSCLC cells results in the concomitant upregulation of mac25/IGFBP-rP1 and 25.1 To investigate the involvement of mac25/IGFBP-rP1 in the cAMP/IBMX-induced NE-like differentiation in NSCLC cells, we first compared control cells with 0.5 mM cAMP/0.5 mM IBMX-treated cells after 72 h in respect of mac25/IGFBP-rP1 and 25.1 expression. An evaluation of mac25/IGFBP-rP1 and 25.1 mRNA expression in control and treated cells by RNase protection assay (RPA) and semiquantitative reverse transcriptase-PCR (RT-PCR) revealed that mac25/ IGFBP-rP1 expression increased up to 9.6-fold (Po0.01) in NCI-H157 cells (Figure 3a ). In the poorly differentiated Lu-CSF-1 cells, mac25/IGFBP-rP1 mRNA was expressed at high levels in basal conditions and no change was seen with cAMP/IBMX treatments. Similar patterns of expression were also noted for 25.1, where mRNA expression increased up to 2.1-fold (Po0.01) in NCI-H157 cells following treatment, but again levels were already high in control Lu-CSF-1 cells and seemed to be uninfluenced by cAMP/IBMX treatments ( Figure 3b) . Likewise, an assessment of mac25/IGFBP-rP1 and 25.1 protein levels in whole-cell lysates (WCL) revealed that mac25/IGFBP-rP1 and 25.1 protein expression increased significantly in NCI-H157 cells following treatment with cAMP/IBMX (Figure 3c ), while expression levels in Lu-CSF-1 cells remained unchanged (data not shown). When compared to the controls, NCI-H157 cells treated with 0.5 mM cAMP/ 0.5 mM IBMX had up to a twofold (Po0.01) increase in accumulated mac25/IGFBP-rP1, which increased further to threefold (Po0.01) when treated with 1 mM cAMP/0.5 mM IBMX (Figure 3c ). Likewise, a 2.5-fold (Po0.01) increase was observed for endogenous 25.1 expression in NCI-H157 cells treated with 0.5 mM cAMP/0.5 mM IBMX (Figure 3c ). The lack of a significant response in Lu-CSF-1 cells suggests that either the mac25/IGFBP-rP1 and 25.1 protein levels are already maximal or a more potent stimulus is required. Overall, the cAMP/IBMX treatments significantly influenced the mac25/IGFBP-rP1 and 25.1 mRNA and protein expression in the less-differentiated NCI-H157 NSCLC cell line, providing evidence that mac25/ IGFBP-rP1 and 25.1 may be involved in the cellular differentiation of these cells by cAMP.
Overexpression of the mac25/IGFBP-rP1 and 25.1 induces NE-like differentiation in NSCLC cells To determine whether the mac25/IGFBP-rP1 and 25.1 play a functional role in the NE differentiation of NSCLC cells, a recombinant adenoviral expression system with tetracycline suppressible regulation was developed for both mac25/IGFBP-rP1 and 25.1, as described in the Materials and methods. To test the functionality of this expression system, both NSCLC cell lines, NCI-H157 and Lu-CSF-1, were infected with either mac25/IGFBP-rP1 (Ad:rP1) or 25.1 HA (Ad:25.1 HA ) in the presence of Ad:TA with SFM or 1% SCM using an optimized multiplicity of infection (MOI) or viral particles per cell. The MOI for each cell line was determined by the adenoviral infection of EGFP (Ad:EGFP), and testing EGFP expression and viral toxicity on near confluent cells for up to 72 h and beyond ( Figure 4a ). The MOI for confluent NCI-H157 and Lu-CSF-1 NSCLC cell lines were optimized at 50 and 500 viral particles per cell, respectively, when assessed by Ad:EGFP. Following infection of Ad:rP1 and Ad:25.1 HA using the optimized MOI, an analysis over a 72 h time course in NCI-H157 and Lu-CSF-1 cells of mac25/IGFBP-rP1 and 25.1 showed a clear and steady increase in the expression of both proteins in a time-dependent fashion and at the expected molecular weight (Figure 4b ). It was also observed at later time points, 63 and 72 h, respectively, that lower molecular weight mac25/IGFBP-rP1 species were present. These lower molecular weight bands, specific to mac25/ IGFBP-rP1, are thought to be products of processing or proteolysis as suggested by Ahmed et al. (2003) , and are presently under investigation. The suppressible function of tetracycline was also tested on the expression of Ad:rP1 and Ad:25.1 HA after a 72 h incubation period in SFM or 1% SCM. As shown by the representative figure, a dose-dependent decrease in protein synthesis for mac25/IGFBP-rP1 was observed in both cell lines with increasing tetracycline concentrations confirming a functionally active system for protein expression using a tetracycline on/off system ( Figure 4c ).
To determine whether mac25/IGFBP-rP1 and 25.1 could play a functional role in the NE differentiation of lung cancer cells, both NCI-H157 and Lu-CSF-1 cells were coinfected with Ad:rP1 and Ad:25.1
HA for up to 72 h in SFM or 1% SCM and compared with coinfected cells grown in the presence of 0.5 mg/ml tetracycline. The results were first assessed immunocytochemically with a polyclonal mac25/IGFBP-rP1 antibody and a monoclonal HA antibody specific to the HA tag of 25.1 to visualize their acquired morphology with coinfection. In both cell lines, those cells clearly overexpressing both mac25/IGFBP-rP1 and 25.1 showed a differentiated phenotype, characterized by the presence of neuronallike processes in a variety of stages in NCI-H157 cells and an exaggerated slender morphology in Lu-CSF-1 cells (Figure 5a ). Results of this morphological investigation suggest that the coinfection of mac25/IGFBP-rP1 and 25.1 induces cellular differentiation of the NSCLC cell lines.
Originally, 25.1 was isolated and characterized as a mac25/IGFBP-rP1 interacting protein. Their combined expression resulted in the differentiation of M12 prostate cancer cells . To establish if the observed differentiation in the NSCLC cells could be the result of the interaction between adenovirus transduced mac25/IGFBP-rP1 and 25.1 proteins, a coimmunoprecipitation (co-IP) study was performed using adenovirally infected NCI-H157 cells. Using polyclonal anti-25.1 as the IP antibody in WCL isolated from NCI-H157 cells overexpressing Ad:25.1 HA for 72 h, 25.1 HA was isolated and subsequently incubated with control conditioned medium from NCI-H157 cells expressing Ad:rP1 in the presence of tetracycline, or conditioned medium from cells overexpressing Ad:rP1 for 72 h. Reverse co-IP experiments were also performed (data not shown). When the co-IPs were evaluated with polyclonal mac25/IGFBP-rP1 and 25.1 antibodies, as well as the monoclonal HA antibody, it was established that adenovirally produced mac25/IGFBP-rP1 and 25.1 HA were able to interact in vitro (Figure 5b) . Overall, the results of this investigation suggest that the interaction of mac25/IGFBP-rP1 and 25.1 result in differentiation of NSCLC cell lines.
To determine whether the differentiated phenotype induced in both NSCLC cell lines by the coexpression of mac25/IGFBP-rP1 and 25.1 HA could be NE-like differentiation, the expression of the well-characterized NE markers, ChrA and NSE, were investigated by two HA at an MOI 50 for 0-72 h in 1% SCM. CM (20 ml) or WCL (10 mg) were run on a 12.5% SDS-PAGE under reducing conditions. Membranes were incubated with polyclonal anti-mac25/IGFBP-rP1 or anti-25.1 antibodies. (c) NCI-H157 cells infected with Ad:rP1 at an MOI 50 for 72 h in 1% SCM with 0-1 mg/ml tetracycline administered every 24 h. CM (20 ml) were run on a 12.5% SDS-PAGE under reducing conditions. Membranes were incubated with polyclonal antimac25/IGFBP-rP1. Each panel is representative of three independent experiments performed in either SFM or 1% SCM. independent methodologies following infection in the presence or absence of 0.5 mg/ml tetracycline for up to 72 h. In both SFM or 1% SCM, immunocytochemical evaluations showed that mac25/IGFBP-rP1 and 25.1 coinfected cells colocalized with both NSE or ChrA in both NCI-H157 and Lu-CSF-1 cells, in contrast to coinfected cells incubated in the presence of tetracycline (Figure 6a ). Cells presumably expressing only Ad:25.1 HA (Figure 6a) or Ad:rP1 (data not shown) did not colocalize with NE markers. Likewise, NSE expression studied by WIB steadily increased over a 72 h time course of infection in NCI-H157 cells, with an induction observed as early as 6 h postinfection (Figure 6b ). Coinfected cells incubated in the presence of tetracycline from 0 to 72 h showed no significant change in NSE expression over time (Figure 6b ). To test further whether exogenous mac25/IGFBP-rP1 could also regulate NSE expression, NCI-H157 cells that had been preinfected with Ad:25.1 HA for 36 h were either infected with Ad:rP1 or treated with CM (obtained from NCI-H157 cells that had been infected with Ad:rP1 for 48 h) for another 36 h. Expression levels of NSE were similar between Ad:rP1-infected cells and exogenous mac25/ IGFBP-rP1-treated cells, and much higher than control cells (Figure 6c ). Similar time course experiments performed in Lu-CSF-1 adenocarcinoma cells resulted in a modest enhancement of NSE expression after 72 h in either SFM or 1% SCM (Figure 6d) . Overall, the differentiated phenotype induced in both NSCLC cell lines by the coexpression of mac25/IGFBP-rP1 and 25.1 HA exhibits NE-like characteristics, suggesting that mac25/IGFBP-rP1 and 25.1 may have a functional role in NE differentiation of lung cancer cells.
NE differentiation is usually regarded as a terminal process. To establish whether the NE-like cellular differentiation observed for both NSCLC cell lines induced by the coexpression of mac25/IGFBP-rP1 and 25.1 (Figure 7a ). This effect is not a result of the cells undergoing senescence, as an assay for b-galactosidase activity (Dimri et al., 1995) on similarly infected NCI-H157 cells detected no activity (data not shown). A cell cycle analysis was performed on NCI-H157 cells that were left untreated or infected with Ad:rP1 and Ad:25.1 HA in the presence or absence of 0.5 mg/ml tetracycline in SFM for 8 days. No evidence of apoptosis was evident, although there was a great decrease in the cell population in the S phase and an increase in the cell population in the G 0 /G 1 phase of the cell cycle (Figure 7b ).
This preliminary investigation suggests that NE-like cellular differentiation induced either by the coexpression of mac25/IGFBP-rP1 and 25.1 HA or the administration of cAMP/IBMX may represent a terminally differentiating phenotype, but clearly this should be verified by a more extensive evaluation.
Discussion
The mechanisms regulating the differentiation process of lung cancer cells are of interest, inspired by the clear need to target and develop more effective therapies for lung cancer patients. This report focuses on NE cells found in lung tumors and the NE-differentiation process. NSCLC that contain foci of NE cells constitute 10-35% of all NSCLC and have been proposed to be an intermediary step between NSCLC and SCLC (Graziano et al., 1994; Linnoila et al., 1994; Gosney et al., 1995; Pelosi et al., 2003) . Thus, the NE differentiation of NSCLC represents an excellent model for understanding the regulatory aspects of NE differentiation in lung cancer and thus the identification of key regulatory proteins for therapeutic targets. In the present study, we investigated mac25/IGFBP-rP1 and a novel interacting protein, 25.1, as potential key regulators of NE differentiation in NSCLC. Observing differential levels of expression between a limited panel of SCLC and NSCLC cell lines, we showed that increasing cAMP levels not only caused NE-like differentiation of NSCLCs, as previously described in prostate cancer cells (Heasley, 2001 ), but also regulated mac25/IGFBPrP1 and 25.1 expression, suggesting that they may be involved in the differentiation process of lung cancer. Regulated coexpression studies in NSCLC cell lines strongly suggest that together mac25/IGFBP-rP1 and 25.1 play a key functional role in the NE-differentiation process of NSCLCs, thus introducing a potential novel regulatory mechanism for NSCLC cells.
The mac25/IGFBP-rP1 protein was previously cloned and identified in a number of systems and is recognized by an array of names including mac25 (Murphy et al., 1993) , tissue adhesion factor (Akaogi et al., 1994) and prostacyclin-stimulating factor (Yamauchi et al., 1994) . Mac25/IGFBP-rP1 shares approximately a 30% identity at the amino-acid level to the IGFBP family of proteins, with high homology to the amino-terminal domain of the IGFBPs and the conservation of critical cysteines (Swisshelm et al., 1995) . A functional relationship to the IGFBPs was established with the exhibition of a low affinity binding of mac25/IGFBP-rP1 to IGF-I and -II, with a 5-to 6-fold lower affinity for IGF-I and a 20-to 25-fold lower affinity for IGF-II, in comparison to IGFBP-1 to -6 (Oh et al., 1996; Hwa et al., 1999) . Since then the influence of mac25/IGFBP-rP1 on the actions of IGFs have begun to emerge Haugk et al., 2000) , although there is enough evidence to suggest a predominant IGF-independent role for this protein. The biological actions of mac25/IGFBP-rP1 appear to be divergent. Presently, mac25/IGFBP-rP1 has been proposed to be a potential tumor suppressor, supported by data showing a downregulation of mac25/ IGFBP-rP1 in specific primary tumors versus normal tissues including meningiomas versus benign leptomeningeal cells (Murphy et al., 1993) and primary prostate tumors versus normal prostate stroma and glandular epithelium (Lopez-Bermejo et al., 2000) . Moreover, mac25/IGFBP-rP1 has been shown to inhibit the growth of malignant human prostate epithelial cells in soft agar as well as tumor formation in nude athymic mice (Sprenger et al., 1999) , while it has been implicated as a senescence-associated factor in breast epithelial cells (Swisshelm et al., 1995; Burger et al., 1998) . Alternatively, mac25/IGFBP-rP1 has been shown to stimulate the proliferation of fibroblasts (Akaogi et al., 1996) and has a high level of expression in proliferating myoblasts, a level of expression that declines with the differentiation of myoblasts into myotubes (Haugk et al., 2000) .
The differential biological role of mac25/IGFBP-rP1 across cellular systems led to a previous investigation in our laboratory for key interacting proteins that could influence the actions of mac25/IGFBP-rP1. Via a yeast two-hybrid screen using mac25/IGFBP-rP1 as bait, a novel cDNA was identified and designated 25.1 . This ubiquitously expressed protein was shown to interact with mac25/IGFBP-rP1, while a combined overexpression of mac25/IGFBP-rP1 and 25.1 in M12 prostate cancer cells, stably expressing mac25/IGFBP-rP1, caused their morphological differentiation and an increased expression of the NE marker, ChrA . Results suggested that 25.1 was a key mac25/IGFBP-rP1-interacting protein and that this interaction was capable of inducing NE-like differentiation of M12 prostate cancer cells. Our investigation on the mac25/IGFBP-rP1 and 25.1 axis in a panel of NSCLC cell lines versus SCLC, well characterized as NE neoplasms, revealed the existence of a differential pattern of expression. The highest levels of both mac25/IGFBP-rP1 and 25.1 were observed in the more neuroendocrine SCLC cells, suggesting that mac25/IGFBP-rP1 and 25.1 may contribute to the growth regulation and differentiation of lung cancers with NE features. As described previously, 10-35% of NSCLC possess NE features, identified by immunocytochemical analyses using a panel of NE markers such as ChrA, NSE, Leu-7 and mucin (Gazdar et al., 1988; Graziano et al., 1994; Linnoila et al., 1994; Wallace, 2002) . Of this population, 19% of large cell carcinomas and 15% of adenocarcinomas exhibited NE characteristics, while only 4% of squamous cell carcinomas exhibit NE features (Linnoila et al., 1994) . From the panel of cell lines included in this investigation, the squamous NCI-H157 and CSCC20 cell lines appeared to express lower levels of mac25/IGFBP-rP1 and 25.1, but a quantitative evaluation of mac25/IGFBP-rP1 and 25.1 between the different subclasses of NSCLC based on the NE characteristics requires a more in-depth investigation.
The molecular regulation of the NE-differentiation process in lung cancer is to date not known. Numerous investigations with prostate cancer model systems have shown that the NE-differentiation process involves a complex interplay of extracellular signals and crosstalk between signaling pathways. Alterations in the microenvironment of the cell such as androgen withdrawal and EGF, IL-6, epinephrine, forskolin and cAMP administration each induce NE differentiation in prostate cancer cells. Meanwhile, the withdrawal of the latter substances results in the loss of the NE phenotype (Vossler et al., 1997; Chen et al., 1999; Deeble et al., 2001) . The most profound effects were observed when cotreatment with the cytokine IL-6 and a variety of PKA activators enhanced the NE differentiation of LNCaP cells (Deeble et al., 2001) . Likewise, microenvironmental changes known to cause NE differentiation in the prostate elicited similar effects in both the poorly differentiated squamous (NCI-H157) as well as the adenocarcinoma (Lu-CSF-1) NSCLC cell lines. Treatment with cAMP/IBMX combinations resulted in distinct morphological changes, growth suppression and the enhanced expression of NE markers. Of note, the most dramatic changes were observed in the poorly differentiated NCI-H157 squamous cell line. Interestingly, cAMP treatments concordantly influenced mac25/ IGFBP-rP1 and 25.1, suggesting that these proteins were either end products or were functional regulators of the NE-differentiation process in NSCLC, regulated by increases in cAMP levels. However, the regulated coexpression of mac25/IGFBP-rP1 and 25.1 via tetracycline responsive adenoviral expression in NSCLC cells indicated that through an interaction these proteins appear to play a functional role in the NE differentiation of NSCLCs. Expressed collectively, mac25/IGFBPrP1 and 25.1 resulted in the development of dendritic processes, and an increase in the expression of classic NE markers such as ChrA and NSE as early as 6 h infection. Long-term treatment (8 days) of mac25/ IGFBP-rP1 further exhibited a significant decrease in cellular proliferation. This growth inhibitory effect is attributed to an induction of cell cycle arrest in the G 1 phase, not to apoptosis or senescence. Further studies indicate that treatment of cAMP/IBMX or overexpression of mac25/IGFBP-rP1 and 25.1 resulted in the inhibition of cyclin A expression, thereby arresting the cell cycle in the G 1 phase for NCI-H157 cells (data not shown).
The possible means by which mac25/IGFBP-rP1 and 25.1 may regulate the NE-differentiation process in the limited panel of NSCLCs used in the current study can be hypothesized based on extensive studies in prostate cancer, where foci of NE cells develop frequently. It is known in LNCaP prostate cancer cells that an increase in intracellular cAMP levels activate the cAMP-dependent PKA and the small G protein Rap-1, which subsequently activates the MAPK pathway (Chen et al., 1999) . The clear involvement of PKA was shown by the development of NE features in LNCaP cells with the expression of a constitutively active PKA catalytic subunit, which is normally released from a heterotetrameric complex by PKA activators such as cAMP (Cox et al., 2000) . In PC12 phaeochromocytoma cells, elevated cAMP alternatively activated the MAPK pathway via B-Raf-and Raf-1-dependent pathways leading to the activation of Elk-1 transcription factors and NE differentiation (Vossler et al., 1997) . Mac25/ IGFBP-rP1 and 25.1 may be collectively involved in cAMP activation of the MAPK pathway via PKAmediated events or events independent of the PKA pathway. Each protein has a putative nuclear localization sequence (NLS) and endogenous expression of both proteins has been reported to be nuclear, with newly synthesized 25.1 reported to go directly to the nucleus ). This suggests involvement of mac25/IGFBP-rP1 and 25.1 in nuclear events. However, mac25/IGFBP-rP1 is a secreted protein in most cells (Oh et al., 1996) , so its participation in the activation of the MAPK cascade, whether it involves cellular export or autocrine/paracrine actions/import, remains to be investigated. Current data indicate that secreted mac25/ IGFBP-rP1 also regulates NSE expression similar to that observed in mac25/IGFBP-rP1-expressing cells in the presence of 25.1, suggesting that autocrine/paracrine-derived secreted mac25/IGFBP-rP1 has to be internalized into cells, and interacts with 25.1, thereby exerting its biological function. Further experiments with NCI-H157 cells expressing mac25/IGFBP-rP1 or 25.1, with mutant NLS along with components of the MAPK cascade, may begin to address the mechanisms of action for these proteins and their importance in the NE differentiation of NSCLC cells.
Alternate mechanisms for the mac25/IGFBP-rP1 and 25.1 induction of NE-like differentiation in NSCLCs are possible. In some of the few studies examining NE differentiation in lung cancer, the MAPK pathway via Raf-1 and the activation of PKC were implicated in the regulation of cell growth and differentiation of SCLC cells by neuropeptides (Heasley, 2001; Jull et al., 2001) , while expression in lung tumors of the oncogene bcl-2, a recognized antiapoptotic marker, has been suggested to correlate closely with NE differentiation (Jiang et al., 1996) . Such examples suggest multiple possibilities for the participation of mac25/IGFBP-rP1 and 25.1 and show that NE differentiation of NSCLC may involve a number of pathways.
SCLC tumors are usually more responsive to initial chemotherapy than NSCLC tumors (Graziano et al., 1994) . One potential explanation for this initial chemotherapeutic sensitivity has been attributed to the NE characteristics of SCLC. Likewise, early stage NE differentiation of NSCLC has been proposed to correlate with early dissemination and metastases as well as favorable early responses to chemotherapy in a number of early investigations (Berendsen et al., 1989; Shaw et al., 1993; Graziano et al., 1994; Linnoila et al., 1994; Schleusener et al., 1996; Iyoda et al., 2001) . In more recent studies, that correlation now seems less well defined (Jiang et al., 1999; Graziano et al., 2001; Yesner, 2001; Gajra et al., 2002) . Nevertheless, recent studies using more defined NSCLC specimens demonstrated that stage I adenocarcinomas with more than 5% NE tumor cells are clinically aggressive tumors, and hormone production identifies a more fully developed NE phenotype but is not relevant to prognosis (Pelosi et al., 2003) . Therefore, it seems more likely that study of a subset of NE-like differentiated NSCLC, delineated using NE markers as part of a more global determination scheme, can still be useful. Hence, understanding the molecular mechanism regulating NE differentiation of lung cancer cells still may have important therapeutic implications. In the present investigation, we have established that mac25/IGFBP-rP1 and 25.1 may play a functional role in the NE-like differentiation process thus introducing a novel regulatory mechanism for the NE-differentiation process of NSCLCs and a potential novel therapeutic target.
Materials and methods

Cell culture
The human NSCLC squamous cell line, NCI-H157 and the SCLC cell lines NCI-H209, HTB-173, NCI-N417 and NCI-H1417 were purchased from American Type Tissue Collection (ATCC; Manassas, VA, USA). The human NSCLC adenocarcinoma cell lines, Lu-CSF-1 and Lu-CSF-1-NCS, the NSCLC squamous cell line, OHSU-9803, and the head and neck squamous cell line, CSCC20, were isolated and characterized by Dr Helen Ross and Dr Chris Corless of the Oregon Cancer Center, OHSU, OR, USA. The NSCLC NCI-H157 cell line and the SCLC cell lines NCI-H209, HTB-173, NCI-N417 and NCI-H1417 cells were cultured in RPMI-1640 medium (Mediatech, Inc., Herndon, VA, USA) supplemented with 300 mg/l L-glutamine, 25 mM HEPES and 10% FBS (Mediatech). The NSCLC cell line Lu-CSF-1 was cultured in DMEM supplemented with 4.5 g/l glucose, 110 mg/l sodium pyruvate and 5% FBS (Gibco BRL, Rockville, MD, USA) and 5% newborn calf serum (NCS; Gibco BRL). The NSCLC cell line, Lu-CSF-1-NCS, were cultured in DMEM supplemented with 4.5 g/l glucose, 110 mg/l sodium pyruvate and 5% NCS. The NSCLC cell line, OHSU-9803, and the CSCC20 cell line were cultured in DMEM supplemented with 4.5 g/l glucose, 110 mg/l sodium pyruvate and 10% FBS. All cell lines were maintained at 371C in a humidified atmosphere of 5% CO 2 . Cells were treated up to 72 h in either fresh SCM, medium containing 1% FBS (1% SCM) or serum-free medium (SFM) as described.
Western immunoblot (WIB)
Following treatments, WCL were prepared in RIPA buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 1% Triton-X 100, 1% sodium deoxycholate, 0.1% SDS, EDTA-free protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN, USA)). Protein concentrations were determined using the BCA Protein Assay (Pierce, Rockford, IL, USA) and sizefractionated on a 10 or 12.5% SDS-PAGE under reducing conditions. Proteins were electrotransferred onto immunoblot polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA, USA). Membranes were incubated with the indicated primary antibodies and detected with the appropriate horseradish peroxidase-conjugated secondary antibody (1:10 000; Southern Biotechnology Associates Inc., Birmingham, AL, USA). Primary antibodies used for WIB included polyclonal anti-mac25/IGFBP-rP1 (1:3000; Wilson et al., 1997) , and anti-25.1 (1:3000; Wilson et al., 2001) as well as a monoclonal anti-neuron specific enolase (anti-NSE; 1:1500; NeoMarkers, Union City, CA, USA) and monoclonal anti-bactin (1:4000) or anti-a-tubulin (1:10,000) as controls (Sigma Chemical Co., St Louis, MO, USA). Immunoreactive proteins were detected using enhanced chemiluminescence (NEN, Boston, MA, USA) and autoradiography (Kodak X-Omat Blue XB-1, Eastman Kodak Co., Rochester, NY, USA) with results quantified by densitometry (GS-700 Imaging Densitometer; Bio-Rad) using QuantityOne software (Bio-Rad).
Immunocytochemistry
For immunoflourescence studies, cells were seeded in eightwell chamber slides (Nalge Nunc International, Naperville, IL, USA) and left to reach 60-70% confluency, upon which they were serum cleared overnight (O/N). Cells were treated for 72 h with either fresh SFM or SCM containing 0.5 mM 8-bromo cAMP (Sigma Chemical Co., St Louis, MO, USA), 1 mM cAMP, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX; Sigma), 0.5 mM cAMP with 0.5 mM IBMX or 1 mM cAMP with 0.5 mM IBMX. Following treatments, cells were fixed with 4% paraformaldehyde, permeabilized using a 1:1 mixture of methanol and acetone, and blocked in 1% bovine serum albumin (BSA; Sigma) with 1% normal goat serum (Sigma) in 1 Â PBS. Primary antibodies used for immunocytochemistry included a monoclonal anti-chromogranin A (anti-ChrA; 1:1000; DAKO, Botany, NSW, Australia), monoclonal antineuron specific enolase (anti-NSE; 1:400), polyclonal antimac25/IGFBP-rP1 (1:400) and polyclonal anti-25.1 (1:400) and monoclonal anti-hemagglutinin (anti-HA; 1:400; Roche). Primary antibodies were detected using fluorescent-conjugated secondary antibodies (goat anti-rabbit IgG or goat anti-mouse IgG 2b conjugated to fluoroscein (FITC) or Texas Red (TR: 1:400; Molecular Probes, Eugene, OR, USA)) collectively with Hoechst DNA stain (1 mg/ml). Results were viewed with an inverted phase fluorescent microscope (Nikon USA, Melville, NY, USA) and images were captured with a MicroMAX digital camera (Princeton Instruments, Princeton, NJ, USA).
RNA extraction, semiquantitative RT-PCR and RPA Lung cancer cells at 60-70% confluency were serum cleared O/ N and treated in SFM or SCM with cAMP/IBMX combinations for 72 h. Total RNA was extracted using the QIAGEN RNeasy Mini Kit according to the manufacturer's instructions (QIAGEN Inc., Valencia, CA, USA) with concentration and integrity confirmed by denaturing gel electrophoresis. The RNA for the RT-PCR was treated with RQ1 RNase-free DNase (Promega) and reverse transcribed using AMV reverse transcriptase according to the manufacturer's instructions (Promega). The PCR was performed using 50 ng of template and 1 mM of primers for 25.1 (forward 5 0 -GGAGATGATCA GGTCAAGGAAGG, reverse 5 0 -GGTGCTTTGCCCAAGG CCCCT) and mac25/IGFBP-rP1 (forward 5 0 -AGGTCAG CAAGGGCACCT, reverse 5 0 -GTTCTGTCCT TTGAACTC CAT) and the internal control beta-2-microglobulin (b2M; forward 5 0 -ACCCCCACTGAAAAAGATGA, reverse 5 0 -ATCTTCAAACCTCCATGATG). The PCR products were evaluated at 29, 32, 35 and 38 cycles to ensure that results would be evaluated during the linear phase of amplification, with 35 cycles selected for the semiquantitative analysis. For the RPA experiments, antisense single-stranded 32 P-labeled mac25/IGFBP-rP1 or 25.1 probes were generated using the Promega Riboprobe System (Promega) according to the manufacturer's instructions. The 32 P-labeled probes were individually incubated with 8 mg of total cellular RNA O/N at 421C in hybridization buffer (20 mM Tris-HCl pH 7.5, 1 mM EDTA, 400 mM NaCl, 0.1% SDS, 75% v/v Formamide). Resulting RNA/RNA hybrids were incubated with a cocktail of RNase A and RNase T1 at 301C, precipitated and run on an 8 M urea, 8% denaturing PAGE gel. The mRNA expression for mac25/IGFBP-rP1 and 25.1 were detected with BioMax MS film (Eastman Kodak Company). Results were quantified by densitometry using QuantityOne software and normalized to total RNA.
Adenoviral construct preparation and infection
Ad:25.1 HA and Ad:mac25/IGFBP-rP1 are dE1-dE3 recombinant adenovirus expressing the human 25.1 tagged with HA and mac25/IGFBP-rP1 genes under the control of a tetracycline (Tet)-responsive P hCMV-1 promoter (Tureckova et al., 2001) . The pShuttle plasmid (transfer vector; Quantum Biotechnology, Montreal, Canada) in an AdEasy Adenovirus Recombinant Kit was manipulated to insert a poly-A signal and P hCMV-1 (Tet R pro), which contains the Tet-responsive element (TRE) (pShuttle:TetR). An adenoviral vector expressing the tetracycline-inhibited transcriptional activator (Ad:tTA) was generated as previously described (Tureckova et al., 2001) . P hCMV-1 is activated through the binding of TA to the TRE in the absence of tetracycline (Clontech Laboratories Inc., Palo Alto, CA, USA). The human 25.1 tagged with HA and mac25/IGFBP-rP1 genes were cloned as a BamH1 (bluntended using Klenow fragment polymerase)-XbaI fragment in the EcoRV-XbaI site of the pShuttle:TetR plasmid. The shuttle vectors obtained, pShuttle:25.1 HA and pShuttle:-mac25/IGFBP-rP1, were homologously recombined with pAdEasy (adenoviral genome plasmid) in BJ5183 Escherichia coli. After recombination, the recombinant adenoviral genome was excised by PacI digestion and the Ad:25.1 HA and Ad:mac25/IGFBPrP1 virus were recovered by transfecting 10 mg of PacI-digested DNA into 293 cells by the FuGENE 6-based procedure (Roche Molecular Biochemicals). An adenoviral plasmid containing enhanced green fluorescent protein (Ad:EGFP) was engineered by digesting pEGFPN1 (Clontech Laboratories Inc.) with SalI and XbaI to generate a 680 bp fragment encompassing the EGFP coding region, which was subsequently cloned into pShuttle:TetR. All viral stocks were prepared from infected 293 cells according to the manufacturer's recommendation. After two-step purification on cesium chloride gradients, viral titers were estimated by OD 260 nm readings and expressed in PFU/ml. Successful mRNA and protein expression of Ad:25.1 HA and Ad:mac25/IGFBP-rP1 were verified by RT-PCR and WIB. Infections were performed in SFM or 1% SCM in either the presence or absence of tetracycline at 0.5 mg/ml administered every 24 h for the suppression or expression of gene-specific protein synthesis, respectively.
Immunoprecipitation (IP)
IPs were performed by incubating 10 mg of WCL isolated from Ad:25.1 HA infected NCI-H157 cells with 1.5 ml of the 25.1 polyclonal antibody in 1 Â PBS O/N at 41C with gentle mixing. After the addition of protein A sepharose (Amersham Pharmacia Biotech AB, Uppsla, Sweden), the incubations were left for an additional 24 h. Immunoprecipitates were then washed four times with ice-cold 1 Â PBS and resuspended in 25% v/v CM from NCI-H157 cells infected with Ad:rP1 in the presence or absence of 0.5 mg/ml tetracycline in 1 Â PBS and incubated O/N at 41C with gentle mixing. Immunoprecipitates were then washed a further four times with ice-cold 1 Â PBS and resolved on a 10% SDS-PAGE gel under reducing conditions. Coimmunoprecipitated proteins were examined by WIB using polyclonal mac25/IGFBP-rP1 and 25.1 and monoclonal HA antibodies.
b-Galactosidase assay for senescence Following treatment, cells were washed in 1 Â PBS, fixed in 0.2% glutaraldehyde, 5 mM EGTA, 2 mM MgCl 2 in 40 mM citric acid/sodium phosphate, pH 6.0, for 15 m at RT, and washed 2 Â 5 m in 2 mM MgCl 2 in 40 mM citric acid/sodium phosphate, pH 6.0. Cells were incubated O/N at 371C in staining solution: 2 mM MgCl 2 , 5 mM potassium ferrocyanide (K 4 Fe(CN) 6 ), 5 mM potassium ferricyanide (K 3 Fe(CN) 6 ), 150 mM NaCl in 40 mM citric acid/sodium phosphate, pH 6.0, to which 50 mg/ml 5-bromo-4-chloro-3-indolyl b-D-galactoside (X-gal) in N,N-dimethylformamide is added to a final 1 mg/ml and filtered. The staining solution was removed, and the cells were washed and scored for blue staining (Dimri et al., 1995) .
Cell cycle analysis/propidium iodide staining Infected and control NCI-H157 cells were trypsinized, washed twice in 1 Â PBS, and resuspended at 1 Â 10 6 cell/ml in 3.8 mM sodium citrate, 0.05 mg/ml propidium iodide, 0.1% Triton X-100 and 10 U Ribonuclease A/ml. The cell suspension incubated 5 h at RT wrapped in aluminum foil before analysis on a Coulter Epics XL-MCL Flow Cytometer at the Flow and Image Cytometry Facility in the Massey Cancer Center at VCU.
Cell growth
To assess cell toxicity and cell proliferation following indicated treatments, trypan blue staining and the cell proliferation assay CellTitre 96
s AQ ueous One were used (Promega Inc., Madison, WI, USA) according to the manufacturer's protocols. Results, where shown, are presented as MTT arbitrary units at A 405À492 .
Statistical analysis
Data are expressed as mean7standard error of the mean (s.e.m.). Differences between two groups were evaluated using an unpaired Student's t-test, where Po0.05 was used to indicate statistical significance.
Abbreviations NE, neuroendocrine; SCLC, small-cell lung carcinoma; NSCLC, non-small-cell lung carcinoma; mac25/IGFBPrP1, mac25/insulin-like growth factor-binding protein-related protein 1.
